After hours: 5:28PM EDT
|Bid||48.77 x 800|
|Ask||49.73 x 1800|
|Day's Range||48.94 - 49.61|
|52 Week Range||33.93 - 56.71|
|Beta (3Y Monthly)||0.81|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.35 (0.71%)|
|1y Target Est||N/A|
Dentsply Sirona Inc (NASDAQ: XRAY ) is in the midst of a major transition. Potential cost savings should support EPS, and the dental equipment supplier could achieve more consistent revenue growth due ...
DENTSPLY SIRONA Inc NASDAQ/NGS:XRAYView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for XRAY with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding XRAY totaled $3.40 billion. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Dentsply Sirona Inc is a designer, developer, manufacturer and marketer of consumable dental products for the professional dental market. The dividend yield of Dentsply Sirona Inc stocks is 0.73%. Warning! GuruFocus has detected 2 Warning Signs with XRAY.
Stocks that moved substantially or traded heavily on Friday: Gap Inc., up $4.11 to $29.51 The retailer behind its namesake and Banana Republic brands will spin off Old Navy into a publicly traded company. ...
Investing.com - The S&P; 500 racked up solid gains Friday to close above a key level, shrugging off data pointing to slowing U.S. economic and global growth as hopes of a U.S.-China trade deal kept risk appetite alive.
Shares of Tesla fell 7.84 percent after the company's underwhelming announcement that it will be launching its standard Model 3. Barclays analyst Brian Johnson even called it the " un-iPhone moment ." The electric car maker also announced store closures and layoffs in an effort to reduce costs, in addition to stating that the company will not turn a profit during its first quarter. Nektar Therapeutics NKTR — The biopharmaceutical fell nearly 6 percent Friday after reporting fourth-quarter earnings.
DENTSPLY SIRONA's (XRAY) overall growth strategy depends on product innovation and R&D focus, which is likely to drive the top line in Q4.
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align Technology (NASDAQ:ALGN) dropped sharply at the open despite beating earnings and revenue estimates. The San Jose-based manufacturer of scanners and aligners used in orthodontics reported double-digit revenue and earnings increases. However, Align stock initially fell on weakened pricing for Invisalign. Still, traders appeared to interpret the drop as a knee-jerk reaction. By the middle of the day, the stock erased all of the losses and had turned positive, closing up about 2.6%. Both the quick recovery and the growth of its popular Invisalign orthodontic product show that Align stock is a buy on any pullback. ### ALGN Stock Is Driven by Robust Growth… And Hesitation For the fourth quarter, ALGN reported GAAP EPS of $1.20 per share. Wall Street had expected $1.14 per share. The company earned only 13 cents per share in the same quarter last year. Revenues of $534.02 million also came in $19.4 million higher than expectations. They also increased 26.7% from year-ago levels when the company reported quarterly revenue of $421.3 million. InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 5 Top Consumer Stocks for 2019 -- According to Wells Fargo The stock might have experienced a carryover of some of the emotion from the previous earnings report. Like many tech stocks, ALGN stock peaked in early October. It then began to plunge. That culminated in a one-day drop of about 20% following its third-quarter earnings report. Align stock has remained in a range since. However, the initial drop following Q4 earnings may have served as a catalyst for an upward move. Given the Q4 numbers, it makes little sense that Align stock plunged at the market open. Yes, the average selling prices on its popular Invisalign clear aligners fell on a year-over-year basis. Invisalign differentiates Align from firms such as Dentsply Sirona (NASDAQ:XRAY) and Danaher (NYSE:DHR) -- who focus more on consumables and equipment. For this reason, Invisalign-related news often drives the equity. Still, with overall profit growth much higher, that fact seems less relevant. ### Earnings May Have Become a Catalyst for Align Stock Traders appear to have come to the same conclusion. Align stock began the trading day by falling almost 7% from the previous close. However, by the middle of the day, the stock was trading above levels of the prior day. I think the early buyers made the correct call. ALGN's forward P/E ratio stands at around 40. Diluted earnings also increased by 73.9% for the year to $4.92 per share. The current 2019 earnings forecast of $5.83 per share would take profit growth down to 18.5%. Still, considering those growth levels, the P/E does not appear elevated. Admittedly, valuations had probably moved ahead of themselves following the increases ALGN saw for most of 2018. Many key patents on Invisalign expired at the end of 2017. When traders saw profit increases continuing without the Invisalign patent protection, they continued to bid up the stock price for 2018. This set up for the fall that began in October. As a result, Align stock has fallen by about 45% from its 52-week high. However, ALGN stock now trades at a much lower multiple. With its years-long track record of double-digit earnings increases expected to continue, investors should treat any moment of panic as a buying opportunity. ### The Bottom Line on Align Stock In an ironic twist, signs of softness in pricing may have become the catalyst that Align stock needs to resume growth. ALGN handily beat earnings and revenue expectations in its Q4 report. However, the stock initially sold off as reports of lower pricing for its Invisalign orthodontic product weighed on the equity. * 10 Stocks to Sell in February Still, as the trading day went on, buyers erased that loss and bid the ALGN stock price above yesterday's closing levels. Traders likely saw an opportunity as the company growth levels remain on track. If the move higher continues, the bright smiles that Align makes possible will go well beyond the orthodontic practices it serves. As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Smart Money Stocks to Buy for the Rest of the Year * 10 Best Consumer Stocks to Buy in 2019 * 10 Triple-A Stocks to Buy in February Compare Brokers The post Earnings Report Brings Brighter Smiles to Align Stock Investors appeared first on InvestorPlace.
Waters Stock Soars after Strong Financial ResultsStock performanceYesterday, Waters (WAT) stock closed at $229.51, ~12.69% higher than its prior closing price of $203.66 and ~37% higher than its 52-week low of $167.93 on October 23. It also hit a
The bears tried to drive the market to a second consecutive losing day on Wednesday, but when push came to shove as the closing bell approached, the bulls stepped up. The S&P 500's close of 2,638.70 yesterday was a 0.22% improvement on Tuesday's last trade, and left stocks at least a little better positioned to resume the recovery effort that got going in late December. International Business Machines (NYSE:IBM), amazingly, led the way with an 8.5% advance after posting better-than-expected fourth quarter results. Waters Corporation (NYSE:WAT), however, technically saw the bigger gain, rallying 13.1% in response to its impressive Q4 report. Tesla (NASDAQ:TSLA), meanwhile, lost another 3.8% on reports that it was cutting production hours for the Model S as well as the Model X and receiving a corresponding downgrade from RBC. InvestorPlace - Stock Market News, Stock Advice & Trading Tips News-driven stocks are tough, if not impossible, to trade though, as their stock charts are always one headline away from the complete reversal of a well-developed trend. Traders seeking better prospects may want to instead look at the stock charts of Applied Materials (NASDAQ:AMAT), Fortinet (NASDAQ:FTNT) and Dentsply Sirona (NASDAQ:XRAY). Here's why. ### Applied Materials (AMAT) Way back on Nov. 21, Applied Materials was featured as a potential rebound candidate. A couple of days of big gains on even bigger volume hinted there were some potential buyers waiting in the wings that would undo the damage done over the course of 2018. * 7 Stupidly Cheap Stocks to Buy Now The breakout thrust never really took shape. A falling resistance line going all the way back to March's peak got in the way. It's still standing, but as of this week it's under attack again. In the meantime, another key line has come into play. Click to Enlarge • The bigger-picture resistance line is plotted as a dashed line on the weekly chart. Last week's gain bumped into it, and though down in the meantime, AMAT is still within striking distance. • In the meantime, the buyers have started to test the gray 100-day moving average line as technical resistance. If it's cleared, it could be catalytic. • Though the potential recovery is huge, suspiciously missing from the mix thus far is decent buying volume. Applied Materials may need to clear its hurdles first before those buyers emerge. ### Fortinet (FTNT) Fortinet shares have made no net progress, up or down, since early November. Rather, they've just bounced around within a narrowing range. That could be about to change, however, with an explosive move, that unleashes all the increasingly pent-up action that has been kept in check be narrowing boundaries. The matter will come to a head as of today. Click to Enlarge • On Thursday, the purple 50-day moving average line will cross below the white 200-day line, forming a so-called 'death cross' that portends more bearishness. Though we don't see the usual bearishness one would expect to accompany a death cross, the event itself may well inspire a refreshed selling effort. • Even if the death cross spurs selling, Fortinet won't be beyond salvaging until and unless it crosses below the recent lows near $64.50. That floor is plotted on the daily chart as a yellow dashed line. • Still, don't rule out a bullish move from this consolidation. The weekly chart shows a modicum of bullish interest. The key for the bulls will be clearing the $76.70 area, where FTNT peaked in December and where the gray 100-day moving average line will soon be. ### Dentsply Sirona (XRAY) Finally, on the first trading day of this year, the budding rally from Dentsply Sirona was dissected as a major breakout candidate. It has not disappointed, rallying from $37.21 then to the current price of $41.02, pushing above a relatively important resistance level in the meantime. As of yesterday, though, the next likely hurdle has come into play. Clearing it will be tough, but could be catalytic. Click to Enlarge • That "next likely" hurdle is the 200-day moving average line, plotted in white on both stock charts. The bulls weren't afraid to approach it, but clearly they've yet to push past it. • If the 200-day average is hurdled, the next checkpoint target is around $47.50, marked with a red line. That's the upper end of the gap that was left behind with August's plunge. • Though there's room for a little pushback here, don't dismiss the momentum seen since last month as insignificant. The 20-, 50- and 100-day moving average lines have all made bullish crosses for the first time since late-2017. As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Hot Stocks to Buy Right Now * 7 Stocks That Have Big Headwinds In 2019 * 5 Terrific Tech Stocks That Will Make You Forget About FANG Compare Brokers The post 3 Big Stock Charts for Thursday: Applied Materials, Fortinet and Dentsply Sirona appeared first on InvestorPlace.
Healthcare stocks cover a wide range of equities. Pharmaceuticals, equipment providers, insurers, pharmacies, technology, and even healthcare-related real estate investment trusts (REIT) can all fall under this category. However, these companies all benefit from the same trends. The share of healthcare in the overall U.S. economy continues to grow. The Centers for Medicare and Medicaid Services (CMS) estimates that healthcare encompasses about 17.9% of the U.S. economy. Moreover, with an estimated 10,000 baby boomers aging into Medicare a day, the pressure on limited healthcare resources continues to mount. * 7 Oversold Small-Cap Stocks With Massive Profit Growth While this can mean pain for the healthcare consumer, it can also bring benefit to those who invest in healthcare. With more of the baby boom generation on Medicare, a larger percentage of the population benefits from a healthcare subsidy. This gives a noticeable boost to healthcare stocks. Here are three that could help you benefit from this trend. InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### AbbVie (ABBV) Source: Shutterstock Few healthcare stocks find themselves in a better position for both income and growth potential than AbbVie (NYSE:ABBV). Abbott Laboratories (NYSE:ABT) created AbbVie when it spun off its pharmaceutical division in 2013. After a growth spurt in 2017, ABBV fell as concerns about patent expirations on its blockbuster drug Humira weighed on the stock. Today it trades at about 30% below its 52-week high. However, ABBV stock also looks well-positioned to make a comeback. The Humira-driven swoon in ABBV has taken the forward P/E ratio to around 9.8. This comes in well below the average P/E of 18.2 over the last five years. Moreover, Evaluate Pharma ranks AbbVie's drug pipeline as second-best in the industry for value creation. Also, the company has time to transition to its next high-revenue drug. It will hold a patent on Humira in the U.S. until at least 2022. Analysts also do not seem worried as they predict profit growth of almost 10% per year through at least 2021. Furthermore, Wall Street considers AbbVie a dividend aristocrat due to its previous ties to Abbott. As a result, the company faces tremendous pressure to increase its dividend annually. AbbVie increased its payout from $3.59 per share to $4.28 per share this year. Hence, despite a generous yield of almost 4.9%, investors can probably expect annual increases in future years. Also, I see this massive dividend increase as a vote of confidence in itself. Couple that with the low P/E and the high ratings that AbbVie's drug pipeline has received, and ABBV should be one of the few healthcare stocks which will outperform in both the growth and income categories. ### Teladoc Health (TDOC) Source: MayApps207 via WikiMedia Buying Teladoc Health (NYSE:TDOC) amounts to buying into the future of healthcare. Without a doubt, the 17.9% of the economy that healthcare now consumes weighs heavily on family budgets. Teladoc allows patients to see a licensed doctor at any time via a PC or mobile device, reducing the need to take time off from work. It also saves money as visits can run as low as $40. Telehealth has only begun to realize its potential. Analysts estimate telehealth can handle about one-third of the 1.25 billion office visits that take place each year in the U.S. With Teladoc handling an estimated two million visits in 2018, the company still covers less than 1% of its potential market. Teladoc also shows that it can acquire the right partners to improve its quality and reach more patients. It widened its competitive moat by investing in diagnostic capabilities with a takeover of Best Doctors. It also partnered with CVS Health (NYSE:CVS) to provide care to its customers. Additionally, it boosted its offshore footprint by buying Advance Medical. Advance Medical was the leading telehealth provider outside the U.S. before TDOC purchased the company. Investors should note that TDOC remains expensive. Its price in the $55 per share range places it at around 9.3 times sales. Still, it has fallen almost 40% from its October high. Also, revenue grew by 78% in 2018. Although that growth will fall over time, analysts estimate that the company will turn profitable in 2021. * 10 Growth Stocks With the Future Written All Over Them Teladoc remains one of the more speculative healthcare stocks. However, with a $3.8 billion market cap, and a majority market share in a business that has reached less than one percent of its full potential, Teladoc could become one of the best stocks in healthcare. ### Dentsply Sirona (XRAY) Source: Shutterstock An aging population creates an increasing need for dental care and the equipment provided by Dentsply Sirona (NASDAQ:XRAY). As the ticker implies, Dentsply manufactures dental imaging equipment as well as consumable supplies and specialty dental products. Medicare rarely covers dental needs. However, many consumers place a high value on having a beautiful smile and the ability to chew food. Hence, most customers will spend money on services requiring XRAY's supplies and equipment. This also holds true outside of the U.S. Dentsply Sirona conducts business in over 120 countries. These other countries account for about 65% of the company's revenue. XRAY stock rose steadily between 2009 and 2018. However, in 2018, the stock lost almost half of its value. By late October, it traded as low as $33.93 per share, a level first seen in 2011. The stock sold off for most of the year on lower-than-expected sales. An impairment charge on goodwill and intangible assets in the second quarter hurt earnings. The stock fell by nearly 20% on August 7 following this announcement. However, management responded with a restructuring plan. While that breeds uncertainty, the forecasts indicate an opportunity for buyers. The forward P/E ratio stands at around 18, well below the five-year average of 28.1. Furthermore, analysts predict 11.2% consensus profit growth this year. They also foresee double-digit profit increases through at least 2021. XRAY faced a great deal of pain in 2018. Still, the need for dental supplies and equipment will only rise in the coming years. For this reason, the lower multiple and the predicted profit growth should bring about a recovery in Dentsply Sirona. As of this writing, Will Healy is long TDOC stock. You can follow Will on Twitter at @HealyWriting. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Top 10 Global Stock Ideas for 2019 From RBC Capital * 10 A-Rated Stocks the Smart Money Is Piling Into * 5 Best Bank ETFs for This Week's Earnings Avalanche Compare Brokers The post 3 Healthcare Stocks That Will Keep Your Portfolio Healthy appeared first on InvestorPlace.
Today we'll look at DENTSPLY SIRONA Inc. (NASDAQ:XRAY) and reflect on its potential as an investment. In particular, we'll consider its Return On Capital Employed (ROCE), as that can give Read More...
Tamarack Capital Management is a hedge fund that was founded by Mr. Justin John Ferayorni, its current Chief Investment Officer and Portfolio Manager. Before deciding to start his own firm, Mr. Ferayorni built up serious experience in investing, working as a Healthcare Analyst and Portfolio Manager, and later own as a Director of Research at […]
Jeffrey Ubben‘s ValueAct Capital has delivered some of the biggest returns in the industry during its 19-year history, with its net returns topping 17% on average through 2017. And whereas many successful funds have lagged badly in recent years, ValueAct has continued to excel, outpacing the market between 2013 and 2017. Ubben, who employs a […]